Archive | C17 Research Network RSS for this section

REMINDER: Registrations to apply for the 100% Fund grant in RHABDOMYOSARCOMA are due Sept-13

C17 is pleased to announce a SUPPLEMENTAL COMPETITION for the The 100% Fund Grant Competition targeting rhabdomyosarcoma. This competition does not replace the regular fall competition.  It is an additional funding opportunity.

The purpose of The 100% Fund Grant Competition is to target directly pediatric cancers that are rare and hard to treat—cancers that have not responded to available therapies. Applications addressing rhabdomyosarcoma will be considered for the 2019 100% Fund Grant Competition (Round 3).

Rhabdomyosarcoma funding partners include Fight Like MasonTeam NaomiTeam Finn, and  Coast-to-Coast Against Cancer

Projects can range from discovery to clinical trials, but must be focused towards a treatment intervention. The goal is to fund research with the potential to deliver improved treatment and increased survival rates. 

This supplemental competition will use a very short LETTER OF REGISTRATION, and not a longer letter of intent.

  • The letter of registration (LOR) is due by 13-Sep-2019 (4pm MT).
  • The LOR is NOT REVIEWED.
  • All applicants who submit a registration by the due date will automatically advance to the grant application stage.
  • Grants are due by 25-Oct-2019 (4 pm MT).
  • Results will be returned with sufficient time for unsuccessful applicants to submit to the 2019/2020 C17 grant competition, going directly to the grant stage.
  • The registration form can be downloaded from the link below or from C17.ca.

Files for download

  1. The 100% Fund Rhabdomyosarcoma Round 3 Call for Letters of Registration
  2. C17 100% Fund (Round 3)—Rhabdomyosarcoma LOR form 
    (LOR due 13-Sept-2019 4pm MT)
  3. C17 100% Fund (Round 3)—Rhabdomyosarcoma grant application form (grants due 25 Oct-2019 4pm MT)
  4. C17 Application Instructions and Award Guide (ver 13-Nov-2018)

Application forms and the guidance document also can be downloaded from the C17 website (www.c17.ca) under Committees> Research Network.

NEW⇒C17 100% Fund Grant Competition Targeting RHABDOMYOSARCOMA. Registration due 13-Sept-19. Grants due 25-Oct-19. Spread the word!!

C17 is pleased to announce a SUPPLEMENTAL COMPETITION for the The 100% Fund Grant Competition targeting rhabdomyosarcoma. This competition does not replace the regular fall competition.  It is an additional funding opportunity.

The purpose of The 100% Fund Grant Competition is to target directly pediatric cancers that are rare and hard to treat—cancers that have not responded to available therapies. Applications addressing rhabdomyosarcoma will be considered for the 2019 100% Fund Grant Competition (Round 3).

Rhabdomyosarcoma funding partners include Fight Like MasonTeam Naomi, Team Finn, and  Coast-to-Coast Against Cancer

Projects can range from discovery to clinical trials, but must be focused towards a treatment intervention. The goal is to fund research with the potential to deliver improved treatment and increased survival rates. 

This supplemental competition will use a very short LETTER OF REGISTRATION, and not a longer letter of intent.

  • The letter of registration (LOR) is due by 13-Sep-2019 (4pm MT).
  • The LOR is NOT REVIEWED.
  • All applicants who submit a registration by the due date will automatically advance to the grant application stage.
  • Grants are due by 25-Oct-2019 (4 pm MT).
  • Results will be returned with sufficient time for unsuccessful applicants to submit to the 2019/2020 C17 grant competition, going directly to the grant stage.
  • The registration form can be downloaded from the link below or from C17.ca.

Files for download

  1. The 100% Fund Rhabdomyosarcoma Round 3 Call for Letters of Registration
  2. C17 100% Fund (Round 3)—Rhabdomyosarcoma LOR form 
    (LOR due 13-Sept-2019 4pm MT)
  3. C17 100% Fund (Round 3)—Rhabdomyosarcoma grant application form (grants due 25 Oct-2019 4pm MT)
  4. C17 Application Instructions and Award Guide (ver 13-Nov-2018)

Application forms and the guidance document also can be downloaded from the C17 website (www.c17.ca) under Committees> Research Network.

C17 Research Network Call for Nominations: Clinical Research – Hematology

At this time we are seeking candidates for the position of “Clinical Research – Hematology” on the Research Network Committee. We ask that the candidates have the experience to critique proposed clinical research, and to contribute to the discussion of all submitted research proposals. Applicants do not need to be senior researchers. There are two major time commitments: a half day for LOI review in January and the grant review meeting that occurs during the C17 AGM. Participation on this committee does not exclude from applying for C17 grants.

If you have a colleague who would be an asset to the Research Network committee, please forward this notificatin or send leah.young2@ahs.ca their contact information. Interested applicants should contact either myself or Nada Jabado as soon as possible. Please see the full call below.


The C17 Research Network is pleased to announce the call for members in the following areas:

Clinical Research – Hematology

We ask all who receive this call for nominations to help us to distribute it as widely as possible. Please forward the call for nominations to institutions, organizations and individuals who might be interested in posting and/or responding to it.

How to Submit an Application
Please submit i) your curriculum vitae, ii) an application letter containing your statement of interest, and iii) a letter of support of from your program director by email to Leah Young at leah.young2@AHS.ca on or before April 8, 2019. The call for applicants will be extended if required. The nominee will be selected by the C17 Research Network Committee; all applicants will be notified directly.

In the statement of interest, candidates should highlight their experience to critique proposed research in the area of hematology, as well as to contribute to the discussion of all submitted research proposals. Please highlight other research interests for which the candidate could contribute to the discussion. Applicants do not need to be senior researchers.

Work of the Committee

  • Conduct scientific review of applications submitted to the C17 Research Grant Competition, and make recommendations to the C17 Directors and Executive Council regarding the awarding of Research Grants
  • Set strategic priorities for C17 Research Network activities
  • The Committee meets via email or teleconferences as needed to review letters of intent

Members of the Committee
Members of the committee include those with experience in basic and clinical research who have established reputations in their respective fields, and who share a national vision for research. They will have an affiliation with one of the 17 centres or associated universities. Consideration will also be given to selecting members who represent large and small centres, and institutions across Canada. Members of the C17 Research Committee will serve for a three year term, renewable once.

The Research Committee includes the following members:

  1. Research Network Chair
  2. Outcomes/Quality of Life Research – Psychology
  3. Clinical Research – Hematology
  4. Clinical Research – Oncology
  5. Clinical Research – Stem Cell Transplantation
  6. Qualitative Research – Nursing
  7. Basic Laboratory Research
  8. Translational Research
  9. Epidemiology
  10. Data Management – Clinical Research Coordinator
  11. Small Centre Representative – centres that diagnose fewer than 30 patients per year
  12. Patient/Parent Representative
  13. Ex-officio members

Direct questions regarding the roles and responsibilities of the Research Network Committee to Leah Young (Coordinator, leah.young2@ahs.ca).

REMINDER: Registrations to apply for the 100% Fund grant in infant leukemia due Feb 1

C17 is pleased to announce a call for applications for the The 100% Fund Grant Competition targeting INFANT LEUKEMIA.

The purpose of The 100% Fund Grant Competition is to target directly pediatric cancers that are rare and hard to treat—cancers that have not responded to available therapies. Applications addressing infant leukemia will be considered for the 2019 100% Fund Grant Competition.

Projects can range from discovery to clinical trials, but must be focused towards a treatment intervention. The goal is to fund research with the potential to deliver improved treatment and increased survival rates. 

Please note that this is a reissue of the call for application for research in infant leukemia. The 100% Fund LOI for infant leukemia is now replaced by a Letter of Registration (LOR) that is due by 1 Feb 2019 (4pm MT).  The registration form can be downloaded from C17.ca and asks for brief administrative details, draft project title, research areas and a very brief/general project description. The 100% Fund Grants targeting infant leukemia will be reviewed in conjunction with the ongoing 2018/2019 Round 22 of grants due 13 April 2019.

The submission deadline for C17 LORs is February 01, 2019 at 4 PM MT.

Application forms and the guidance document also can be downloaded from the C17 website (www.c17.ca) under Committees> Research Network.

100% Fund Grant Competition — reissue of call for grants targeting INFANT LEUKEMIA [registration due 01-Feb-2019]

C17 is pleased to announce a call for applications for the The 100% Fund Grant Competition targeting INFANT LEUKEMIA.

The purpose of The 100% Fund Grant Competition is to target directly pediatric cancers that are rare and hard to treat—cancers that have not responded to available therapies. Applications addressing infant leukemia will be considered for the 2019 100% Fund Grant Competition.

Projects can range from discovery to clinical trials, but must be focused towards a treatment intervention. The goal is to fund research with the potential to deliver improved treatment and increased survival rates.

Please note that this is a reissue of the call for application for research in infant leukemia. The 100% Fund LOI for infant leukemia is now replaced by a Letter of Registration (LOR) that is due by 1 Feb 2019 (4pm MT).  The registration form can be downloaded from C17.ca and asks for brief administrative details, draft project title, research areas and a very brief/general project description. The 100% Fund Grants targeting infant leukemia will be reviewed in conjunction with the ongoing 2018/2019 Round 22 of grants due 13 April 2019.

The submission deadline for C17 LORs is February 01, 2019 at 4 PM MT.

Application forms and the guidance document also can be downloaded from the C17 website (www.c17.ca) under Committees> Research Network.

C17 Research Network and 100% Fund Grant Competition — call for LOI [due 14-Dec-2018]

C17 is pleased to announce the call for LOI for the The 100% Fund C17 Grant Competition and Round 22 of the C17 Research Network Operating Grant Competition.

The C17 Operating Grant Competition is focused on multicenter, multidisciplinary pediatric oncology and hematology research.

The purpose of The 100% Fund Grant Competition is to target directly pediatric cancers that are rare and hard to treat—cancers that have not responded to available therapies. Applications addressing the hard-to-treat cancer types below will be considered for the fall 2018 100% Fund Grant Competition.

Please see the calls for LOI, LOI forms and C17 Award Guide documents, linked below.

The submission deadline for C17 LOIs is December 14, 2018 at 4 PM MST.

The application form and guidance document also can be downloaded from the C17 website (www.c17.ca) under Committees> Research Network.

STAY TUNED: Calls for LOI for the C17 Research Network Operating Grant and 100% Fund Grant Competitions are Expected Mid-November

The C17 Research Network anticipates announcing the calls for LOI for the following in mid/early November.

  • Operating Grant competition
  • 100% Fund competition – infant ALL
  • 100% Fund competition – rhabdomyosarcoma

Application forms specific to the competition will be uploaded; no significant changes are expected from the previous grant competition round.

Congratulations to Shane Sinclair from the University of Calgary on the receipt of a C17 Research Network grant targeted at conceptualizing and operationalizing compassion

Grant title: Conceptualizing and Operationalizing Compassion in Pediatric Oncology: The Development of a Patient, Family Member and Healthcare Provider Informed Theoretical Model

Lay abstract:  Compassion is a key component of high quality healthcare. While children and family members increasingly expect compassion and healthcare providers desire to provide it, providing and receiving compassion in the pediatric oncology settings is a growing challenge. Although Canadian Pediatric Society guidelines state that “It is essential that every team member…provide compassionate care that meets or exceeds parents’ expectations,” and the Hospice Palliative Care Association attests that “Pediatric hospice palliative care is provided by an interdisciplinary team of competent and compassionate formal caregivers who work collaboratively with the child and family,” no studies have defined and operationalized compassion within a pediatric setting.

This study will develop a clinically informed, patient and family centered, theoretical model of compassion from the perspective of children living within advanced cancer, their parents and healthcare providers. The aim of this study is to conceptualize and operationalize compassion from the perspective of individuals who are exposed and are challenged to address suffering on a frequent basis. This study will generate a model illustrating the key care domains of compassionate care that healthcare providers need to be cognizant of in order to optimally deliver compassion. While compassion is particularly salient to this population we believe the findings will be of relevance across oncology, BMT and hematology populations.

 

Congratulations to Jason Berman from IWK on the receipt of a C17 Research Network grant targeting neuroblastoma

Grant title: The Microenvironment as a Therapeutic Target in High Risk Neuroblastoma

Lay abstract: Neuroblastoma is one of the most deadly cancers in children. While advances in treatment have made some improvements to survival, more than half of children will still die of disease. When neuroblastoma cells from the initial tumour move to another spot in the body and form another tumour, this is called metastasis and is particularly deadly. Thus, being able to stop cancer cells from spreading to organs like the bone, bone marrow and brain is critical to impacting survival of these vulnerable children. The spread of cancer cells is not only dependent on the cancer cell itself, but also on factors in the surrounding environment, known as the tumour microenvironment. Determining how these factors contribute to the spread of neuroblastoma and either increasing or decreasing these levels could improve current neuroblastoma treatment. We have developed approaches to transplant human cancer cells into zebrafish embryos, which are see-through and have similar cells and organs as humans, providing an environment not dissimilar from what occurs when these cancer cells arise in children. We have further “humanized” these zebrafish by altering them to express certain human factors produced by cells found around cancer cells that may contribute to their movement. We will put human neuroblastoma cells into zebrafish and determine which factors outside and inside the cells affect where these cells travel. Information from these studies will provide guidance as to what factors to block or increase to prevent neuroblastoma spread and improve outcome.